A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)

Conditions

• NonSegmental Vitiligo

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Povorcitinib — DRUG
  Oral, Tablet
• Placebo — DRUG
  Oral, Tablet

Study Details

This study is being conducted to determine the efficacy and safety of povorcitinib in participants with nonsegmental vitiligo.

Key Dates

Start date

Nov 27, 2023

Status verified

Mar 2026

Primary completion

Mar 17, 2026

Completion

Mar 16, 2027

Study Design

Enrollment

450 participants (actual)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Experimental: Povorcitinib Dose A
  Participants will receive Povorcitinib Dose A for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.
• Placebo Comparator: Placebo
  Participants will receive Placebo for 52 weeks, followed by Povorcitinib Dose A for 52 weeks.

Primary Outcome Measure

Proportion of Participants Achieving a ≥ 75% Improvement From Baseline in the Facial Vitiligo Area Scoring Index (F-VASI75) [ Time Frame: Week 52 ]

Locations (33)

Find similar trials in Birmingham, AL

Related Studies

• A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream in Pediatric Participants With Nonsegmental Vitiligo
  PHASE3 · Recruiting · Incyte Corporation · Birmingham, Alabama
• A Study of Zasocitinib in Adults With Nonsegmental Vitiligo
  PHASE2 · Recruiting · Takeda · Bryant, Arkansas